Compare Flagstar Bank NA (FLG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Merck & Co., Inc. — how do they compare? Flagstar Bank NA trades at $15.33 (market cap $6.26B), while Merck & Co., Inc. trades at $126.99 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 48.8× Flagstar Bank NA's market cap, and Merck & Co., Inc. pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| FLG | MRK | |
|---|---|---|
Market Cap | $6.26B | $305.29B |
Sector | Financials | Health |
52-Week High | $15.28 | $129.52 |
52-Week Low | $10.72 | $77.60 |
Dividend Yield | 0.27% | 2.75% |
Enterprise Value | — | $348.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $15.285, up 2.17% today, with a bullish technical signal from moving averages and a consensus analyst price target of $17.05. Recent earnings beat expectations in Q4 2025 and Q1 2026, though the company remains unprofitable on an annual basis with a net income margin of -2.71% in 2026. Positive developments include a proprietary technology transformation and a recent dividend declaration.
The outlook is cautiously optimistic, supported by analyst buy ratings and improving fundamentals, but risks include persistent negative profitability and high interest expenses. Upside is tied to continued execution on the turnaround and future earnings growth.
Merck (MRK) trades at $120.80, down 2.6% on the day, with technical indicators showing a bullish moving average signal but neutral oscillators. The company reported strong recent earnings beats and maintains solid profitability with a 73.91% gross margin and 13.59% net margin. Recent news highlights Merck's acquisition of Terns Pharmaceuticals for approximately $6.7 billion to bolster its oncology pipeline, while institutional investors continue accumulating shares.
The outlook remains positive with analyst consensus at Buy (67.57%) and a $137.30 price target, suggesting 13.7% upside. Key risks include integration challenges from the Terns acquisition, competitive pressures in oncology, and potential regulatory headwinds. Strong cash flow generation ($16.47B operating cash flow in 2025) supports continued dividend payments and strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
